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Abstract
Background: Hereditary angioedema (HAE), caused by deﬁciency in C1-inhibitor
(C1-INH), leads to unpredictable edema of subcutaneous tissues with potentially
fatal complications. As surgery can be a trigger for edema episodes, current
guidelines recommend preoperative prophylaxis with C1-INH or attenuated
androgens in patients with HAE undergoing surgery. However, the risk of an
HAE attack in patients without prophylaxis has not been quantiﬁed.
Objectives: This analysis examined rates of perioperative edema in patients with
HAE not receiving prophylaxis.
Methods: This was a retrospective analysis of records of randomly selected
patients with HAE type I or II treated at the Frankfurt Comprehensive Care
Centre. These were examined for information about surgical procedures and the
presence of perioperative angioedema.
Results: A total of 331 patients were included; 247 underwent 700 invasive proce-
dures. Of these procedures, 335 were conducted in 144 patients who had not
received prophylaxis at the time of surgery. Categories representing signiﬁcant
numbers of procedures were abdominal (n = 113), ENT (n = 71), and gynecologi-
cal (n = 58) procedures. The rate of documented angioedema without prophylaxis
across all procedures was 5.7%; in 24.8% of procedures, the presence of perioper-
ative angioedema could not be excluded, leading to a maximum potential risk of
30.5%. Predictors of perioperative angioedema could not be identiﬁed.
Conclusion: The risk of perioperative angioedema in patients with HAE type I or
II without prophylaxis undergoing surgical procedures ranged from 5.7% to
30.5% (CI 3.5–35.7%). The unpredictability of HAE episodes supports current
international treatment recommendations to consider short-term prophylaxis for
all HAE patients undergoing surgery.
Hereditary angioedema (HAE) is a relatively rare autosomal
dominant condition caused by a deﬁciency in C1-inhibitor
(C1-INH), the primary control protein for the complement
system that regulates vascular permeability (1–3). In 85% of
affected patients, the levels of functional C1-INH are low
(~30% of normal levels) (HAE-I) (4, 5), while 15% of
patients have normal or raised levels of nonfunctional
C1-INH (HAE-II) (6). C1-INH deﬁciency results in inappro-
priate or excessive activation of the complement pathway
and allows the activation of kallikrein, which leads to
production of the vasoactive peptide bradykinin (2, 3).
Clinical symptoms of HAE include edema of the subcuta-
neous (SC) tissues of the extremities, abdomen, face and
larynx (7). Untreated attacks normally last for 3–5 days, and
edema of the upper airways is considered life-threatening due
to the risk of asphyxiation (5, 8). The onset of symptoms
typically occurs in childhood, with increased symptoms often
seen during puberty, and recurrent attacks occurring
throughout life (3). In most cases, HAE attacks are sponta-
neous in nature, and trigger factors cannot generally be iden-
tiﬁed, resulting in unpredictable ﬁrst manifestations and
recurrences (1, 3–5, 9). However, speciﬁc trigger factors asso-
ciated with HAE attacks include oral surgery (including
dental work), mechanical stress and exertion, minor injuries
and trauma, infections, emotional stress and excitement,
insect stings, certain foods and medicines, and menstruation
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to patient and even within patients, thus making manage-
ment of the disorder difﬁcult (1, 3–5, 9, 15).
Due to the increased likelihood of edema posed by
emotional stress and physical trauma, surgery and minor
manipulations or intubation pose a challenge in patients with
HAE. Infusions of plasma-derived or recombinant C1-INH
concentrate (Berinert
, CSL Behring; Cinryze
, ViroPharma;
and Ruconest
TM, Swedish Orphan Biovitrum) and subcutane-
ous (SC) administration of the bradykinin B2 receptor antag-
onist Icatibant (FIRAZYR
, Shire) have proven effective in
the treatment for acute HAE attacks (16–20), while preproce-
dural infusions of plasma-derived C1-INH can be effective in
preventing angioedema associated with dental or surgical
procedures (21–23). International (9) and British (4) consen-
sus papers have recommended that administration of prophy-
lactic doses of HAE medication may be advisable under
certain circumstances, including during the perioperative per-
iod in case of an edema episode. Current guidelines recom-
mend C1-INH for prophylactic use prior to surgery in the
ﬁrst instance (9, 24). Where C1-INH is not available, attenu-
ated androgens or antiﬁbrinolytics are recommended as alter-
natives (9, 24).
Although the risk of angioedema associated with surgery
or even minor invasive or surgical procedures is well known,
no systematic data on the risk of angioedema in patients
without prophylaxis have yet been published. Such an analy-
sis could provide evidence to support current recommenda-
tions for patients with HAE undergoing surgery.
In this article, we report a single-centre, retrospective anal-
ysis of the risk of angioedema in patients with HAE types I
and II associated with operative and invasive procedures
without preprocedural or concomitant long-term prophylaxis.
This analysis of patient records included patients undergoing
any surgical procedures, thus reﬂecting the whole range of
routine clinical practice.
Methods
This was a retrospective analysis of patients with HAE types
I and II treated at the Frankfurt Comprehensive Care Cen-
tre. The centre has a database of 640 adult and pediatric
patients with C1-INH deﬁciency, from which 331 patients
from all ages were randomly selected for assessment. For this
analysis, every second patient (in alphabetical order) from
the database was selected, thus avoiding potential bias such
as severity of HAE. This study focused on surgery without
HAE prophylaxis, and patient cases were included irrespec-
tive of the year in which the procedure occurred.
Patients’ records were examined for information about
type of HAE (I or II), previous procedures, including time
and type of procedure, type of prophylaxis if any (preproce-
dural short-term prophylaxis with C1-INH or long-term pro-
phylaxis with attenuated androgens), number of individual
procedures per patient, and presence or absence of periopera-
tive angioedema.
Individual procedures were excluded from further analysis
if prior to the procedure the patients were on long-term
prophylaxis with attenuated androgens, or if plasma-derived
C1-INH had been administered for short-term prophylaxis.
No further potential preprocedural prophylactic measures
were documented (e.g., use of fresh frozen plasma, antiﬁbrin-
olytic agents).
Dental procedures were excluded from the analysis to
avoid bias as most dental procedures are perceived as rela-
tively minor and are often only reported if adverse events
have been experienced. Other exclusion criteria included
known HAE type III and acquired C1-inhibitor deﬁciency.
We evaluated the risk of perioperative angioedema in those
patients not receiving short- or long-term prophylaxis overall
and by type of surgical procedure, using descriptive statistics.
Only procedures with documented angioedema were
included in the calculation of minimum risk of an HAE epi-
sode, while the sum of this frequency plus the percentage of
procedures with unrecorded outcome was used as an estimate
for maximum risk. Conﬁdence borders of 2.5% and 97.5%
are provided for the minimum risks or the maximum risks,
respectively, for the overall population of procedures and
some subgroups of subjects and of procedures.
Results
The characteristics of the patients included in this analysis
are shown in Table 1. The majority of patients had HAE
type I. A total of 331 patients were included, of whom 247
patients (74.6%) underwent a total of 700 invasive proce-
dures (an average of 2.8 procedures per patient). The types
of procedures most commonly reported were abdominal
(187/700; 26.7%), gynecological (142/700; 20.3%), orthopedic
(115/700; 16.4%), or ear, nose, and throat (ENT) (112/700;
16.0%) (Fig. 1).
A total of 335 procedures were conducted in 144 patients
who did not receive any prophylaxis at the time of surgery
(Table 2). Fifty percent of procedures without prophylaxis
for which the date was recorded occurred after 1984. Periop-
erative angioedema was recorded in 19/335 (5.7%) of proce-
dures overall and was explicitly documented as not having
been observed in 233/335 (69.6%). In the remaining 24.8%
of procedures (83/335), the presence or absence of angioe-
dema was not recorded (Fig. 2). Therefore, it can be
estimated that the general risk of perioperative angioedema
Table 1 Breakdown of patient age, sex, and HAE type
Patients with
procedures
Patients
without
procedures
Patients 247 100% 84 100%
HAE-I 230 93% 78 93%
HAE-II 17 7% 6 7%
Male 89 36% 37 44%
Female 158 64% 47 56%
Age, y (mean, range) 43.9
(1–91)
26.6
(1–80)
Age <18 years 23 10% 32 38%
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between 5.7% and 30.5% (CI: 3.5, 35.7%). Angioedema risk
for procedures performed after 1984 was similar (range
between 6.0% and 27.1%). The majority of procedures there-
fore did not result in angioedema.
The rates of angioedema across the various categories of
surgical procedure are reported in Fig. 3. Categories repre-
senting signiﬁcant numbers of procedures were abdominal
(n = 113), ENT (n = 71), gynecological (n = 58), and ortho-
pedic (n = 45) procedures. Examples of the range of proce-
dures within each category are given in Table 3. Estimates
for minimum and maximum risk of perioperative angioedema
were 3.5–29.2% for abdominal (CI: 1.0, 38.5%), 4.2–32.4%
for ENT (CI: 0.9, 44.6%), 6.9–32.8% for gynecological
(CI: 1.9, 46.3%), and 11.1–31.1% for orthopedic procedures
(CI: 3.7, 44.6%).
A total of 19 procedures (5.7%) resulted in perioperative
angioedema. These procedures included gynecological and
abdominal surgery such as hysterectomy with and without
ovariectomy (three cases), appendectomy (two cases), lapa-
roscopy, laparotomy, tubal ligation, and an operation on
ureterolithiasis (one case each). Edema also occurred in other
types of operations such as knee surgery (three cases),
adenectomy with and without tonsillectomy (two cases), hip
surgery, orchidopexia, and reposition of nose fracture (one
case each). However, minor procedures like suture of a the-
nar cut and injection of hyaluronic acid in the lips also
caused postoperative angioedema (hand swelling and severe
facial edema). A total of 7/19 patients with reported periop-
erative swelling underwent at least one further procedure
without experiencing edema.
In most cases of perioperative angioedema, swelling was
located at the site or region of surgery. However, one case of
hand swelling after hysterectomy and another of foot edema
after appendectomy were recorded. Three episodes of laryn-
geal edema were documented after laparoscopy (one case)
and adenotomy with and without tonsillectomy (two cases).
In two patients, perioperative angioedema was the ﬁrst mani-
festation of HAE. One involved laryngeal edema following
laparoscopy, requiring re-intubation.
Despite a lack of preprocedural or long-term prophylaxis,
233 procedures (69.6%) were completed without angioedema-
related sequelae. These included a range of major procedures
normally requiring prolonged operation and intubation or
associated with a large degree of tissue damage. These
included vertebral column operations (four procedures), kid-
ney transplant, multiple organ surgery (hysterectomy, partial
colon and bladder resection), cystectomy and prostatectomy,
nephrectomy, resection of neuroblastoma, and operation on
compartment syndrome (one of each procedure).
There was a trend toward a higher maximum risk of
angioedema in HAE type II compared with HAE-I, with
15.4% minimum risk and 38.5% maximum potential risk in
HAE-II (CI: 4.4, 59.4%) vs 4.9% minimum risk and 29.8%
maximum potential risk in HAE-I (CI: 4.1, 35.2%).
Women with HAE-I and -II experienced more cases of
perioperative angioedema compared with men: 4.8% (11/228)
minimum risk, 36.0% (82/228) maximum potential risk in
women (CI: 2.4, 42.6%) vs 7.5% (8/107) minimum risk and
Figure 1 Types of surgery recorded (both with and without prepro-
cedural prophylaxis).
Table 2 Breakdown of procedures by patient age, sex, and HAE
type
Procedures
No prophylaxis (ﬁnal analysis) 335
HAE-I (%) 309 (92%)
HAE-II (%) 26 (8%)
Male (%) 107 (32%)
Female (%) 228 (68%)
Age <18 years (%) 19 (6%)
Age 18 years (%) 316 (94%)
Figure 2 Risk of angioedema during 335 procedures conducted in
patients not receiving any prophylaxis for HAE prior to surgery.
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Discussion
Aside from the surgical or diagnostic procedure itself, the
risk of angioedema may be inﬂuenced by associated factors
such as anesthesia, psychological stress, underlying disease,
proximity to mucous membranes, position on the surgical
table, and use of compression (25). For minor manipulations,
such as mild dental procedures, current international HAE
treatment guidelines recommend that no routine prophylaxis
is required if C1-INH is immediately available (26). When
performing more than mild manipulation, C1-INH prophy-
laxis should be considered (26). Where C1-INH is not avail-
able, short-term prophylaxis with attenuated androgens is
recommended, even in children or during the last trimester of
pregnancy (it is, however, recommended that this approach
should be avoided in the ﬁrst two trimesters). For intubation
or major procedures, C1-INH should ideally be administered
1 h presurgery, or as close to, but no more than 6 h before
commencement of the procedure. The recommended dose is
10–20 units per kg. A second dose of equal amount should
be immediately available at the time of surgery, and doses
should be repeated daily as needed until there is no further
risk of angioedema (24).
The current study is the ﬁrst to investigate the risk of
angioedema in patients with HAE undergoing surgery and
invasive procedures without the use of prophylactic treatment
to prevent an HAE episode. To date, no attempt has been
made to identify which patients are at greatest risk of an
HAE episode or circumstances contributing to occurrence.
This study found that a small proportion of procedures
without prophylaxis caused angioedema in HAE-I and -II
compared with the rate expected based on perceived risk.
The observed overall risk (5.7–30.5%) of angioedema in our
retrospective analysis is comparable with that reported in the
study by Bork et al., in which 21.5% of patients without pro-
phylaxis experienced angioedema after tooth extraction and
12.5% of patients experienced angioedema with prophylaxis
(21). There was no signiﬁcant difference in risk between
abdominal, ENT, gynecological and orthopedic procedures
due to the broad conﬁdence intervals.
The categorization of procedures by site used here was
chosen for clinical reasons and does not necessarily indicate
severity or extent of surgery but rather anatomical site.
Within the category of abdominal surgery, appendectomy
was the most frequent location, possibly related to a high
percentage of unrecognized abdominal HAE episodes
(Table 3). The extent of the surgical trauma involved did not
seem to be a strong predictor of angioedema rates, with
major procedures being among those less linked to angioe-
dema. Apart from mechanical trauma, the psychological
stress related to surgery or invasive procedures, as well as
underlying diseases may have contributed to the manifesta-
tion of angioedema. Thyroid procedures, which like dental
procedures might be anticipated to be associated with high
rates of local (e.g laryngeal) angioedema, were not associated
with perioperative angioedema in the nine cases examined
here.
Our results show that perioperative angioedema may occur
as the ﬁrst clinical manifestation of HAE. The beneﬁt of
knowing patient HAE status prior to surgical procedures and
the importance of having a readily available supply of acute
treatment (such as C1-INH concentrate) in the emergency
setting is clear. Individuals with HAE should share that
information with family members, and members of families
with a history of HAE should be encouraged to seek diagno-
sis and/or share that information with their physicians.
Patients should, when possible, carry an emergency card with
relevant treatment information.
Figure 3 Risk of angioedema in patients not receiving any prophy-
laxis prior to surgery by procedure.
Table 3 Procedures without prior prophylaxis–distribution of most common surgical procedure sites by category
Abdominal n ENT n Gynecological n Orthopedic n
Appendectomy 62 Tonsillectomy (TE) 35 Cesarean section 15 Knee 15
Herniotomy 19 Adenotomy (AT) 13 Hysterectomy 11 Ankle 5
Cholecystectomy 10 Maxilla/sinus 6 Tubes/ovaries 11 Vertebra 4
Laparoscopy 7 TE+AT 5 Abrasion/abortion 8 Fractures 4
Miscellaneous 15 Miscellaneous 12 Miscellaneous 13 Miscellaneous 17
All sites 113 All sites 71 All sites 58 All sites 45
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in patients with HAE-I and -II reported after different surgi-
cal procedures without prophylaxis identiﬁed in our study,
our data highlight the unpredictable nature of acute HAE
episodes and raise the need for routine consideration of
preprocedural prophylaxis in patients with HAE.
The presence of perioperative angioedema after one proce-
dure did not predict the outcome of further procedures
regarding angioedema complications. This unpredictability
makes it difﬁcult to identify those patients at higher risk of
an HAE episode in whom prophylaxis may be beneﬁcial.
This is particularly important considering the fact that
angioedema can have severe consequences and a potentially
life-threatening impact on the patient.
Potential weaknesses in this analysis include recall-bias,
which may have led to either an over or underestimation of
angioedema risk; another weakness is the lack of reliable
information on the type of anesthesia used, particularly on
intubation prior to surgery. Thus, conclusions cannot be
drawn regarding the risk of angioedema associated with dif-
ferent types of anesthesia. Due to the broad range of risk
estimated, it was not possible to distinguish differences in the
risk of an HAE episode, for example, between subgroups of
procedures or patients.
This study demonstrates that surgery or minor manipula-
tions are situations that require special attention in patients
with HAE. In this study, some patients with reported angioe-
dema underwent further procedures without complication,
while a wide range of major surgery did not lead to angioe-
dema complications. However, angioedema was observed in
some cases of minor procedures, and angioedema complica-
tions, when they did occur, were not necessarily conﬁned to
local edema. Furthermore, perioperative angioedema can be
the ﬁrst clinical manifestation of HAE.
The outcome of individual operations in patients with
HAE-I or -II is unpredictable irrespective of type of surgery,
HAE type, gender, or previous preprocedural angioedema
complications. The varied recorded responses to surgical
trauma reﬂect the variability of the disease itself. In elective
surgery, C1-INH concentrate should be immediately at hand
if available to minimize the patients’ risk. However, it is
important to note that HAE should not form a barrier to
patients seeking routine treatments, or lead to a delay in
emergency procedures in the event that prophylaxis is not
immediately at hand (26).
Our ﬁndings in this study, most notably the unpredictabil-
ity of individual periprocedural HAE episodes, support cur-
rent international treatment recommendations to consider
short-term prophylaxis for patients with HAE on an individ-
ual basis.
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